These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24915983)

  • 21. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
    Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
    Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statins targeting inflammation by lowering low-density lipoprotein?
    Tuzcu EM; Nicholls SJ
    J Am Coll Cardiol; 2007 May; 49(20):2010-2. PubMed ID: 17512356
    [No Abstract]   [Full Text] [Related]  

  • 23. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
    Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
    AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?
    Rizzo M; Rini GB; Spinas GA; Berneis K
    Atherosclerosis; 2009 Jun; 204(2):330-3. PubMed ID: 19027905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease.
    Yunoki K; Nakamura K; Miyoshi T; Enko K; Kubo M; Murakami M; Hata Y; Kohno K; Morita H; Kusano KF; Ito H
    Am J Cardiol; 2011 Aug; 108(3):333-9. PubMed ID: 21545981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.
    Makkar KM; Sanoski CA; Goldberg LR; Spinler SA
    Ann Pharmacother; 2013 Nov; 47(11):1457-62. PubMed ID: 24285762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
    Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statins.
    Senaratne J; Griffiths J; MacDonald K; Senaratne MP
    J Cardiopulm Rehabil Prev; 2012; 32(5):250-4. PubMed ID: 22785146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
    Takase S; Matoba T; Nakashiro S; Mukai Y; Inoue S; Oi K; Higo T; Katsuki S; Takemoto M; Suematsu N; Eshima K; Miyata K; Yamamoto M; Usui M; Sadamatsu K; Satoh S; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Egashira K; Sunagawa K
    Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):350-358. PubMed ID: 27932353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus.
    Winkler K; Jacob S; Müller-Schewe T; Hoffmann MM; Konrad T
    Atherosclerosis; 2012 Jan; 220(1):189-93. PubMed ID: 22115011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
    Athyros VG; Tziomalos K; Kakafika AI; Koumaras H; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2008 Feb; 101(4):483-5. PubMed ID: 18312762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
    Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
    Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
    Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.